Brief: Axim Biotech, University Of British Columbia ink clinical study deal
02/08/2017 14:00
Aug 2 (Reuters) - Axim Biotechnologies Inc AXIM.PK
* Axim biotech enters clinical study agreement with
university of british columbia to begin clinical trial on cbd
chewing gum for treatment of drug-related psychosis
Source text for Eikon: ID:nGNXOCTXPa
Further company coverage: AXIM.PK
((Bangalore.newsroom@thomsonreuters.com ;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2